StealthCo - Associate Scientist, In Vitro Pharmacology and Assay Development

Raven Stealth Co - Associate Scientist, In Vitro Pharmacology and Assay Development

About Raven: We are Raven, RA Capital’s healthcare incubator. From discovery to delivery, whether we incubate, accelerate or rejuvenate, Raven’s goal is to turn scientific breakthroughs into transformative therapies and get them quickly, safely and efficiently to the patients that need them most. Raven’s experienced scientists, operators, and healthcare innovators have deep sector expertise across therapeutics, diagnostics, devices and services. They have brought hundreds of therapeutics into development, managed hospital systems, optimized clinical trials and navigated payor and regulatory systems to deliver patient impact - and they are ready to work with you.

About RA Capital: Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our Tech Atlas internal research division, and Raven, RA Capital’s company building team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined.

RA Capital has more than 150 employees and over $10 billion in assets under management.

We are a well-funded, stealth-mode biotechnology focused on next generation oligo-based modalities targeting tissues beyond the liver, muscle, and kidney. We are building a platform to deliver oligos with high precision to previously untargeted cells, while focused on “undruggable” genes, alone or in combination with previously validated targets. Many of our targets carry "pipeline-in-a-drug" potential: a single gene or protein with meaningful biological effects across multiple disease areas.

Headquartered in Cambridge, Massachusetts, the company was incubated in RA Capital’s venture group (Raven) and is led by an experienced CEO. After a robust incubation and vetting process, Raven Stealth Co was launched and funded by RA Capital. The company’s therapeutic areas of interest lie outside commonly targeted cells and tissues, and represent multi-billion-dollar markets that are continuing to grow as the population ages.

Our initial focus is creating transformational therapies to treat diseases, but given the platform potential, we have longer-term ambitions to address healthy aging. These targets are backed by strong biological and genetic evidence but have historically resisted small molecule and biologic approaches. Raven Stealth Co is moving quickly to address multiple disease indications at scale and with significant market potential.

We are in the discovery stage and will invest heavily in our emerging platform for oligonucleotide delivery. Our disease focus offers strong translatability from animal models to humans, which provides a potentially rapid and efficient path to the clinic. Given our recent funding and commitment to building a first-in-class platform, we are recruiting Associate Scientist In Vitro Pharmacology and Assay Development to help build and run the in vitro pharmacology engine (target  pathway validation, oligonucleotide profiling, and mechanism-of-action work) and to execute the ex vivo analyses that turn our externalized in vivo studies into interpretable results.

The Associate Scientist reports to the Director of Biology and Pharmacology and works closely with delivery, conjugation chemistry, and analytical colleagues. This lab-based role spans two capabilities the company cannot advance without: a rigorous in vitro pharmacology engine (physiologically relevant primary and stem-cell-derived models, oligonucleotide screening, mechanism-of-action work), and hands‑on support of our externalized in vivo pharmacology, executing the ex vivo analyses on samples returning from CRO‑run studies in partnership with the in vivo pharmacology lead.

The two are…